Ptc Therapeutics Stock Price, News & Analysis

PTC Therapeutics, Inc. (NASDAQ: PTCT) has received the 2023 EURORDIS Black Pearl Company Award for Innovation, recognizing its 25-year commitment to rare disease research and treatment. The award celebrates organizations making significant advancements in the development of therapies for rare diseases.

CEO Stuart W. Peltz highlighted the importance of this recognition as PTC marks its quarter-century serving the rare disease community. The award ceremony is scheduled for February 21 in Brussels, coinciding with Rare Disease Day, which aims to raise awareness about rare diseases globally.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in the SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 a.m. EST. The company will present a comprehensive overview of its operations and strategic focus. A live webcast of the presentation will be available on PTC's Events and Presentations page and will be archived for 30 days. PTC is dedicated to developing innovative treatments for patients with rare disorders, aiming to maximize access to transformative medicines. For further details, visit www.ptcbio.com.

PTC Therapeutics (NASDAQ: PTCT) announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna™ (ataluren) for reimbursement within the National Health Service (NHS) in England and Wales. This decision makes Translarna the only approved treatment for patients aged 2 and older with nonsense mutation Duchenne muscular dystrophy who can walk. The NICE recommendation is based on clinical trials showing Translarna's effectiveness in slowing disease progression and improving outcomes. This marks a significant milestone for patients and reflects PTC's ongoing commitment to access for effective treatments.

PTC Therapeutics (PTCT) announced the launch of its ninth STRIVE™ awards program aimed at funding initiatives for the Duchenne Muscular Dystrophy (Duchenne) community. Submissions are due by March 17, 2023, with projects focusing on Innovation and Transition to Adulthood. Since its inception in 2015, STRIVE has supported 39 initiatives across 20 countries, addressing the needs of Duchenne patients who now live longer due to improved treatments. This year’s recipients will be announced in September, continuing PTC's 25-year commitment to support the Duchenne community.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on January 5, 2023, the approval of non-statutory stock options for 39,585 shares and 13,045 restricted stock units (RSUs) for 33 new employees as a part of their employment compensation. This follows the NASDAQ inducement grant exception guidelines. The stock options have an exercise price of $39.42 per share, vesting over four years, while the RSUs also vest over a four-year period. These grants are designed to attract talent and align new hires’ interests with the company's long-term goals.

PTC Therapeutics reported a 2022 total revenue of approximately $710 million, showing over 30% year-over-year growth. The company projects 2023 total revenue guidance between $940 million and $1 billion. Significant corporate milestones include the approval of Upstaza™ for AADC deficiency and the initiation of several clinical trials. The unaudited net product revenue in 2022 reached $535 million, with guidance for DMD franchise revenue in 2023 between $545 million and $565 million.

PTC Therapeutics, based in South Plainfield, N.J., will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 a.m. PST/10:30 a.m. EST.

The presentation can be accessed via a live webcast on the company’s Investor section and will be archived for 30 days. PTC focuses on developing medicines for rare disorders, aiming to provide access to transformative treatments for patients with unmet medical needs.

PTC Therapeutics (PTCT) announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This marks a significant milestone as it's the first global approval for Waylivra for this indication. The approval was based on the Phase 2/3 BROADEN study, which demonstrated an 88% mean reduction in triglyceride levels for patients treated with Waylivra at three months, compared to only 22% for the placebo group. Waylivra is also approved for Familial Chylomicronemia Syndrome (FCS) in Brazil.

PTC Therapeutics has received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for Upstaza (eladocagene exuparvovec), the first gene therapy aimed at treating AADC deficiency. This rare disorder severely impacts motor development, posing life-threatening challenges. Upstaza has demonstrated clinical efficacy, allowing patients to achieve significant motor and cognitive milestones after treatment. This authorization follows a similar approval in the European Union, furthering PTC's commitment to innovative therapies for rare diseases.